[Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].
In rodents fenofibrate shares with other triglyceride-lowering agents the potential to increase the liver peroxisome population. It was therefore of interest to look for this effect in hyperlipoproteinemic patients receiving this drug. Light and electron microscopy of liver biopsies from a group of 10 patients treated with fenofibrate and from another group of 13 receiving diet only, show no morphological difference between both groups. In contrast with the rodent data the morphometric study reveals no significant changes in the number (fenofibrate group: 7.96 10(10) cm-3; group receiving diet alone: 8.41 10(10) peroxisomes per cm3 of liver tissue) or in the size (fenofibrate group: diameter = 0.53 +/- 0.07 micron; group receiving diet alone: 0.50 +/- 0.06) of peroxisomes. The difference between our results and those obtained consistently in rodents may be due to the relatively low dose in man and/or a species-dependant difference in enzyme content of liver peroxisomes, itself related to an apparent difference in the way in which lipids are handled.
D000328:Adult; D000368:Aged; D000818:Animals; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects* / Q000031:analogs & derivatives; D006801:Humans; D006951:Hyperlipoproteinemias / Q000178:diet therapy / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008830:Microbodies / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D008854:Microscopy, Electron; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects*
D000960:Hypolipidemic Agents; D011422:Propionates; C006012:fenofibric acid; D011345:Fenofibrate
Etude morphométrique des péroxysomes hépatiques chez des malades hyperlipoprotéinémiques traités par fénofibrate.